吡罗昔康对实验性诱导糖尿病大鼠血视网膜屏障的影响。

Effect of piroxicam on the blood-retina barrier in experimentally induced diabetes in rats.

作者信息

Bahgat M, Anis H H, Peyman G A, Farahat H G, Parry G J, Khoobehi B

机构信息

LSU Eye Center, New Orleans.

出版信息

Int Ophthalmol. 1991 Sep;15(5):335-41. doi: 10.1007/BF00128953.

DOI:10.1007/BF00128953

PMID:1835966

Abstract

The effect of piroxicam on the blood-retina barrier was evaluated in rats with experimentally induced diabetes. Diabetes was induced in rats by intraperitoneal injection of streptozocin (STZ). Diabetic rats were divided into two equal groups: those treated with piroxicam, a long-acting platelet inhibitor, and an untreated control group. Vitreous fluorophotometry (VFP) was performed both before and two weeks after induction of diabetes and piroxicam intake. Streptozocin-induced diabetes caused an alteration in the blood-retinal barrier evidenced by an increase in vitreous fluorescein concentration in diabetic rats compared with normal rats. Piroxicam intake did not lead to significant change in vitreous fluorescein concentrations. However, the examination had to be terminated at two weeks because of cataract formation. The piroxicam treated group showed less incidence of lens opacity formation (59.1% compared to 81.8% in the untreated group, p = 0.0006). Piroxicam administration appears to protect the diabetic rat eye against lens opacification.

摘要

在实验性诱导糖尿病的大鼠中评估了吡罗昔康对血视网膜屏障的影响。通过腹腔注射链脲佐菌素（STZ）诱导大鼠患糖尿病。将糖尿病大鼠分为两组，每组数量相等：一组用长效血小板抑制剂吡罗昔康治疗，另一组为未治疗的对照组。在诱导糖尿病和摄入吡罗昔康之前以及之后两周均进行玻璃体荧光光度测定（VFP）。链脲佐菌素诱导的糖尿病导致血视网膜屏障发生改变，与正常大鼠相比，糖尿病大鼠玻璃体荧光素浓度升高证明了这一点。摄入吡罗昔康并未导致玻璃体荧光素浓度发生显著变化。然而，由于白内障形成，检查不得不于两周时终止。吡罗昔康治疗组晶状体混浊形成的发生率较低（59.1%，而未治疗组为81.8%，p = 0.0006）。给予吡罗昔康似乎能保护糖尿病大鼠的眼睛免受晶状体混浊的影响。